ClinicalTrials.gg
RecruitingNCT06930638MITOUpdated Nov 12, 2026

MitoQ and Ischemic Conditioning To Assess Vascular Health Outcomes

A Phase 2 interventional study of Ischemic Conditioning and Antioxidant Supplement in Stroke, sponsored by Medical College of Wisconsin. Recruiting at 1 site in United States. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Medical College of Wisconsin · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Started Jul 2025; still recruiting 1 year 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 23 studies testing antioxidants in Stroke — 7 open to participants now, 8 under way, 2 of them phase 3. A drug class: Antioxidants · Stroke.

Planned enrollment
19th of 23
30 · median 150
Started
2025
with 3 others
Phase 2
5 of 23
1 open now
Registered
20th of 23
by date

Among the 23 studies testing antioxidants in Stroke, this one is the 19th largest by planned enrollment, is one of 4 that started in 2025, is one of 5 in phase 2, and was the 20th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

7 of the 23 studies testing antioxidants in Stroke are open now, in 3 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

About antioxidants

A class of medicines: which ones, and the studies of each, are on its page →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies testing antioxidants in Stroke, or all of them as a file.
02

Study summary

Stroke survivors have compromised vascular function which may contribute to secondary stroke risk, cardiovascular disease, and may limit their exercise tolerance. Preliminary data shows a single bout of ischemic conditioning or oral ingestion of an over-the-counter antioxidant supplement called MitoQ may improve vascular function and muscle activity in individuals post-stroke.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Ischemic Conditioning
  • Blood Flow
  • Microvascular Health
  • Flow-Mediated Dilation
  • Antioxidant
  • Reactive Oxygen Species
  • Supplement
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • 18 - 85 years of age
  • Cortical or sub-cortical stroke ≥ 6 months ago with residual hemiparesis
  • Able to give and follow 2-step command.
  • English Speaking

Exclusion criteria

Exclusion Criteria:

  • Unable to stand from chair without physical assistance from another person (able to use assistive device).
  • History of blood clots in the extremities or any condition in which compression of the thigh or transient ischemia is (i.e., wounds in the leg).
  • Chronic lasting symptoms (> 6 months) of severe COVID-19 (i.e., hospitalization)
  • History of head trauma or concussion within the past 6 months
  • Comorbid neurological disorder
  • Peripheral vascular disease
  • Myocardial infarction or arrhythmia in the previous year
  • Resting SBP ≥180 mmHg or DBP ≥ 100 mmHg
  • Pregnant or breastfeeding.
  • Other significant medical condition likely to influence study or jeopardize safety as assessed by the Primary Investigator
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Ischemic Conditioning - High

    During each testing session, the investigators will be measuring how one treatment of ischemic conditioning affects blood flow and muscle function. One day participants will receive a high cuff inflation pressure on the leg, called ischemic conditioning - high (225 mmHg).

    Device: Ischemic Conditioning

  • Experimental
    Ischemic Conditioning - Low

    During each testing session, the investigators will be measuring how one treatment of ischemic conditioning affects blood flow and muscle function. One day participants will receive a low cuff inflation pressure on the leg, called ischemic conditioning - low (25 mmHg).

    Device: Ischemic Conditioning

  • Experimental
    Antioxidant Supplement

    During each testing session, the investigators will be measuring how one treatment of an over-the-counter antioxidant supplement affects blood flow and muscle function. One day participants will orally ingest an over-the-counter antioxidant supplement called MitoQ.

    Dietary Supplement: Antioxidant Supplement

Interventions

  • DeviceIschemic Conditioning

    The cuff will be placed around the proximal, non-affected thigh and inflated for 5 minutes in a supine or semi-reclined position, then released for a 5-minute recovery period. Five cycles of inflation and recovery will be performed (45 minutes total).These inflations will be done using a cuff similar to what is used for taking blood pressure.

  • Dietary supplementAntioxidantsStudies of AntioxidantsAntioxidants pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    MitoQ is an over the counter supplement that increases delivery to the mitochondria. Similar to studies performed in middle age/older adults and individuals with peripheral arterial disease, we will administer 1 single oral dose of 80mg of MitoQ or a placebo pill. As MitoQ reaches peak concentrations at \~40 to 60 minutes after ingestion, we will wait 45 minutes (time matched to Ischemic conditioning).

06

What researchers measure

Primary outcomes

  1. Brachial Artery Flow-Mediated Dilation

    We will measure brachial artery vascular health in the non-paretic arm. Baseline brachial artery diameter and blood flow velocity through the artery will be measured before and after a pneumatic forearm cuff is inflated to 225 mmHg for five minutes.

    Time frame: Change from BL to Post Intervention (5 hours)

  2. Microvascular Vasodilation

    Laser Doppler Flowmetry (LDF) with Dermal Microdialysis (DM) will measure blood flow flux during microinfusions of study drugs (limited to an area on the skin approximately the size of a nickel) to examine endothelial dependent vasodilation (Acetylcholine, ACh) and nitric-oxide mediated vasodilation (ACH +/- LNAME, and endothelial nitric oxide synthase inhibitor).

    Time frame: Change from BL to Post Intervention (5 hours)

Secondary outcomes

  1. Muscle Tissue Oxygenation

    We will also place a near-infrared spectroscopy (NIRS) pad on the thenar eminence of the non-paretic hand to non-invasively measure tissue oxygenation via infrared light following the pneumatic forearm cuff inflation/deflation.

    Time frame: Change from BL to Post Intervention (5 hours)

  2. Blood Draw

    We will collect blood before and after the intervention via an in-dwelling intravenous catheter. The blood draw analysis may include but will not be limited to examining complete blood counts, glucose levels, cholesterol, and plasma redox and bioenergetic analyses.

    Time frame: Change from BL to Post Intervention (5 hours)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jul 2025 (actual). Primary completion is estimated for Dec 2026, 17 months after the start.

Of 112 non-industry phase 2 interventional studies under Stroke, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 60. This study's planned 17 months is below that.

Counting every sponsor, half of 132 studies reached it within 40 months; a quarter within 24 and three quarters within 59.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 9, 2025
First posted
Apr 16, 2025
StartActual
Jul 22, 2025
Primary completionEst.
Dec 31, 2026
CompletionEst.
Dec 31, 2026
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: verification date
1 update, last Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    Minor edits only
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06930638
Responsible party
Matthew J. Durand (Associate Professor, Medical College of Wisconsin) — Principal investigator
First posted
Apr 16, 2025
Start date
Jul 22, 2025
Primary completion
Dec 31, 2026 (estimated)
Completion
Dec 31, 2026 (estimated)
Last update
Nov 12, 2026

Study contacts

Jennifer Nguyen
Contact
jnguyen@mcw.edu
414-955-5713
Alicen Whitaker-Hilbig, DPT, PhD
Contact
awhitakerhilbig@mcw.edu
414-955-5713
Matthew Durand, PhD
principal investigator · Medical College of Wisconsin

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Antioxidants

Start the discussion